Cardio-vascular effects of sildenafil: New data;Le sildenafil (Viagra®), 5 ans après: Données actuelles en pathologie cardiovasculaire

Annales de Cardiologie et d'Angeiologie

Volumn 51, Issue 6, 2002, Pages 341-345

  Danchin, N ^a  

^a HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

Author keywords

Arterial vasodilation; Pulmonary hypertension; Sildenafil

Indexed keywords

ANTIHYPERTENSIVE AGENT; CYCLIC GMP; ILOPROST; NITRATE; PHOSPHODIESTERASE INHIBITOR; SILDENAFIL; CGMP BINDING, CGMP SPECIFIC 3',5' CYCLIC NUCLEOTIDE PHOSPHODIESTERASE; CGMP-BINDING, CGMP-SPECIFIC 3',5'-CYCLIC NUCLEOTIDE PHOSPHODIESTERASE; CYCLIC GMP PHOSPHODIESTERASE; PHOSPHODIESTERASE; PIPERAZINE DERIVATIVE; VASODILATOR AGENT;

AGED; ARTERY STEAL SYNDROME; CARDIOVASCULAR DISEASE; CARDIOVASCULAR EFFECT; CORONARY ARTERY BLOOD FLOW; DRUG CONTRAINDICATION; DRUG EFFECT; DRUG FATALITY; DRUG MECHANISM; DRUG SAFETY; EXERCISE TEST; HUMAN; HYPOXIA; LUNG ARTERY PRESSURE; MAJOR CLINICAL STUDY; MALE; PATIENT SELECTION; POSTMARKETING SURVEILLANCE; PULMONARY HYPERTENSION; REVIEW; COMPUTER GRAPHICS; CORONARY ARTERY ATHEROSCLEROSIS; DRUG INTERACTION; HYPERTENSION; LUNG WEDGE PRESSURE;

3',5'-CYCLIC-GMP PHOSPHODIESTERASE; COMPUTER GRAPHICS; CORONARY ARTERIOSCLEROSIS; CORONARY CIRCULATION; DRUG INTERACTIONS; HUMANS; HYPERTENSION; HYPERTENSION, PULMONARY; PHOSPHORIC DIESTER HYDROLASES; PIPERAZINES; PULMONARY WEDGE PRESSURE; VASODILATOR AGENTS;

EID: 0036952919     PISSN: 00033928     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0003-3928(02)00137-3     Document Type: Short Survey

References (17)

1. Kloner RA, Jarow JP. Erectile dysfunction and sildenafil citrate and cardiologists. Am J Cardiol 1999;83:576-82.
2. Boolell M, Allen MJ, Ballard SA, Gepi-Attee S, Muirhead GJ, Naylor AM, Osterloh IH, Gingell C. Sildenafil: an orally active type 5 cyclic GMP-specific phosphodiesterase inhibitor for the treatment of penile erectile dysfunction. Intern J Impotence Res 1996;8:47-52.
3. Jackson G, Benjamin N, Jackson N, Allen MJ. Effects of sildenafil citrate on human hemodynamics. Am J Cardiol 1999;83:13C-20C.
4. Herrmann HC, Chang G, Klugherz BD, Mahoney PD. Hemodynamic effects of sildenafil in men with severe coronary artery disease. N Engl J Med 2000;342:1622-6.
5. Arruda-Olson A, Mahoney DW, Nehra A, Leckel M, Pellikaa PA. Cardiovascular effects of sildenafil during exercise in men with known or probable coronary artery disease. A randomized crossover trial. JAMA 2002;287:719-25.
6. Kloner RA, Brown M, Prisant LM, Collins M, for the sildenafil study group. Effect of sildenafil in patients with erectile dysfunction taking antihypertensive therapy. Am J Hypertens 2001;14:70-3.
7. Shakir SAW, Wilton LV, Boshier A, Layton D, Heeley E. Cardiovascular events in users of sildenafil: results from first phase of prescription event monitoring in England. BMJ 2001;322:651-2.
8. Wysowski DK, Farinas E, Swartz L. Comparison of reported and expected deaths in sildenafil (viagra) users. Am J Cardiol 2002;89:1331-4.
9. Dishy V, Sofowora G, Harris PA, et al. The effect of sildenafil on nitric oxide-mediated vasodilation in healthy men. Clin Pharmacol Ther 2001;70:270-9.
10. Katz SD, Balidemaj K, Homa S, Wu H, Wang J, Maybaum S. Acute type 5 phosphodiesterase inhibition with sildenafil enhances flowmediated vasodilation in patients with congestive heart failure. J Am Coll Cardiol 2000;36:845-51.
11. Prasad S, Wilkinson J, Gatzoulis MA. Sildenafil in primary pulmonary hypertension. N Engl J Med 2000;343:1342.
12. Michelakis E, Tymchak W, Lien D, Webster L, Hshimoto K, Archer S. Oral sildenafil is an effective and specific pulmonary vasodilator in patients with pulmonary arterial hypertension. Comparison with inhaled nitric oxide. Circulation 2002;105:2398-403.
13. Zhao L, Mason NA, Morrell NW, et al. Sildenafil inhibits hypoxia-induced pulmonary hypertension. Circulation 2001;104:424-8.
14. Wilkens H, Guth A, König J, et al. Effect of inhaled iloprost plus oral sildenafil in patients with primary pulmonary hypertension. Circulation 2001;104:1218-22.
15. Ghofrani HA, Wiedemann R, Rose F, et al. Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomized controlled trial. Lancet 2002;360:895-900.
16. Phillips BG, Kato M, Pesek CA, et al. Sympathetic activation by sildenafil. Circulation 2000;102:3068-73.
17. Bocchi EA, Guimaraes G, Mocelin A, Bacal F, Bellotti G, Ramires JF. Sildenafil effects on exercise, neurohormonal activation, and erectile dysfunction in congestive heart failure. A double-blind, placebo-controlled, randomized study followed by a prospective treatment for erectile dysfunction. Circulation 2002;106:1097-103.